Charles Atisso

5.2k total citations · 1 hit paper
18 papers, 864 citations indexed

About

Charles Atisso is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Charles Atisso has authored 18 papers receiving a total of 864 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Charles Atisso's work include Diabetes Treatment and Management (17 papers), Metabolism, Diabetes, and Cancer (14 papers) and Diabetes Management and Research (4 papers). Charles Atisso is often cited by papers focused on Diabetes Treatment and Management (17 papers), Metabolism, Diabetes, and Cancer (14 papers) and Diabetes Management and Research (4 papers). Charles Atisso collaborates with scholars based in United States, Canada and United Kingdom. Charles Atisso's co-authors include Kathleen Dungan, Whitney Sealls, José Gerardo González‐González, Santiago Tofé, Thomas Först, Jessie L. Fahrbach, Mark Lakshmanan, Richard F. Arakaki, Pedro García and Thomas Blevins and has published in prestigious journals such as The Lancet, Circulation and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Charles Atisso

16 papers receiving 840 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

2014 391 citations Kathleen Dungan, Santiago Tofé et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Atisso United States	7	812	465	253	244	84	18	864
Jessie L. Fahrbach United States	12	1.1k 1.3×	462 1.0×	281 1.1×	183 0.8×	84 1.0×	19	1.1k
P. Miossec France	12	991 1.2×	455 1.0×	376 1.5×	204 0.8×	83 1.0×	22	1.1k
Andrei‐Mircea Catarig Denmark	17	899 1.1×	623 1.3×	171 0.7×	241 1.0×	115 1.4×	30	1.0k
Ted Okerson United States	11	845 1.0×	364 0.8×	479 1.9×	255 1.0×	89 1.1×	21	1.0k
Elisabeth Niemoeller Germany	20	1.8k 2.2×	752 1.6×	650 2.6×	264 1.1×	98 1.2×	43	1.9k
Tomoyuki Nishida Japan	14	672 0.8×	324 0.7×	173 0.7×	187 0.8×	86 1.0×	26	723
Erika Rochotte Switzerland	4	891 1.1×	385 0.8×	360 1.4×	162 0.7×	31 0.4×	5	924
Signe Stensen Denmark	11	456 0.6×	245 0.5×	279 1.1×	84 0.3×	103 1.2×	22	595
Deborah T. Cirkel United Kingdom	8	463 0.6×	221 0.5×	157 0.6×	110 0.5×	35 0.4×	8	529
Astrid Breitschaft Denmark	11	406 0.5×	191 0.4×	123 0.5×	165 0.7×	90 1.1×	17	542

Countries citing papers authored by Charles Atisso

Since Specialization

Citations

This map shows the geographic impact of Charles Atisso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Atisso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Atisso more than expected).

Fields of papers citing papers by Charles Atisso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Atisso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Atisso. The network helps show where Charles Atisso may publish in the future.

Co-authorship network of co-authors of Charles Atisso

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Atisso. A scholar is included among the top collaborators of Charles Atisso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Atisso. Charles Atisso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Čižnár, Peter, Marion Roderick, Miloš Jeseňák, et al.. (2024). fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study. Allergy Asthma and Clinical Immunology. 20(1). 47–47. 1 indexed citations

Ferrannini, Giulia, Sohini Raha, Rao Ps, et al.. (2023). Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial. Scandinavian Cardiovascular Journal. 57(1). 2166101–2166101. 7 indexed citations

Кониг, Маниге, Matthew C. Riddle, Helen M. Colhoun, et al.. (2021). Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology. 20(1). 194–194. 42 indexed citations

Riddle, Matthew C., Hertzel C. Gerstein, Denis Xavier, et al.. (2021). Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. The Journal of Clinical Endocrinology & Metabolism. 106(5). 1345–1351. 18 indexed citations

Dagenais, Gilles R., Mark Lakshmanan, Leanne Dyal, et al.. (2020). Abstract 15586: Burden of Cardiovascular or Fatal Outcomes in People With Type 2 Diabetes and Cardiovascular Risk Factors Treated With Dulaglutide a Post Hoc Analysis From the Rewind Trial. Circulation. 142(Suppl_3). 1 indexed citations

Pantalone, Kevin M., et al.. (2020). Cardiovascular outcomes trials with glucagon‐like peptide‐1 receptor agonists: A comparison of study designs, populations and results. Diabetes Obesity and Metabolism. 22(12). 2209–2226. 12 indexed citations

Shaw, Jonathan E., Fady T. Botros, Raleigh Malik, Charles Atisso, & Hertzel C. Gerstein. (2020). Dulaglutide and Kidney Function-Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. Journal of the American Society of Nephrology. 31(10S). 348–348. 1 indexed citations

Shaw, Jonathan E., Fady T. Botros, Raleigh Malik, et al.. (2020). 356-OR: Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. Diabetes. 69(Supplement_1). 3 indexed citations

Colhoun, Helen M., Clinton M. Hasenour, Matthew C. Riddle, et al.. (2020). 924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND. Diabetes. 69(Supplement_1). 2 indexed citations

10.

Umpierrez, Guillermo E., Kevin M. Pantalone, Charles Atisso, Laura Fernández Landó, & Hiren Patel. (2019). Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide. Diabetes Obesity and Metabolism. 21(6). 1365–1372. 5 indexed citations

11.

Umpierrez, Guillermo E., Kevin M. Pantalone, Charles Atisso, Laura Fernández Landó, & Hiren Patel. (2018). Relative Contribution of Basal and Postprandial Hyperglycemia Stratified by A1C Categories Before and After Treatment Intensification with Dulaglutide. Diabetes. 67(Supplement_1).

12.

Ferdinand, Keith C., Fady T. Botros, Charles Atisso, & Philip T. Sager. (2016). Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovascular Diabetology. 15(1). 38–38. 49 indexed citations

13.

Wysham, Carol, Thomas Blevins, Richard F. Arakaki, et al.. (2014). Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care. 37(8). 2159–2167. 321 indexed citations

14.

Dungan, Kathleen, Santiago Tofé, Thomas Först, et al.. (2014). Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. The Lancet. 384(9951). 1349–1357. 391 indexed citations breakdown →

15.

Dungan, Kathleen, Santiago Tofé, Thomas Först, et al.. (2014). Efficacy and Safety of Once Weekly Dulaglutide vs. Once Daily Liraglutide in Type 2 Diabetes (AWARD 6). Canadian Journal of Diabetes. 38(5). S11–S11.

16.

Wysham, Carol, Thomas Blevins, Richard F. Arakaki, et al.. (2014). Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159–2167. Diabetes Care. 37(10). 2895–2895. 4 indexed citations

17.

Wysham, Carol, Thomas Blevins, Richard F. Arakaki, et al.. (2013). 1.2 Efficacy and Safety of Dulaglutide versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1) (66-OR). 11(3). 75–76. 1 indexed citations

18.

Wysham, Carol, Thomas Blevins, Richard F. Arakaki, et al.. (2013). Efficacy and Safety of Dulaglutide Versus Placebo and Exenatide in Type 2 Diabetes (AWARD-1). Canadian Journal of Diabetes. 37. S44–S44. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact